GENEGUT – Oral delivery of encapsulated RNA nanotherapeutics for targeted treatment of ileal Crohn's disease

Using RNA therapy to treat ileal Crohn’s Disease

Revolutionary Crohn's Disease Treatments based on RNA Technology

GENEGUT has one primary ambition: to create a first-of-its-kind, game-changing treatment for ileal Crohn’s Disease, addressing a significant unmet medical need, by making major advances in RNA-delivery technology to inflamed sites in the gut following oral administration.

The delivery of RNA will be enabled by a combination approach where novel biomaterials designed to overcome the barriers in the gastrointestinal tract, are synthesized into nanoparticles (NP) which encapsulate the RNA. Using an industry partner’s emergent capsule platform technology, the RNA is orally administered and locally tackles the inflammation in the intestinal tissue, avoiding systemic side effects.

News

Shifting the focus: the women behind GENEGUT

Logo of the International Day of Women and Girls in Science February 11 is the International Day of Women and Girls in Science. Initiated by

Tweets

Tweets by GENEGUT_EU

About

Coordinated by the University College Cork, GENEGUT brings together 9 Partners from 8 different countries to develop a revolutionary treatment for CD

Crohn's Disease

Affecting about 3 million people in Europe alone, Inflammatory Bowel Disease (IBD) has a drastic impact
on the quality of life – and new therapies are urgently needed

RNA Therapy

Given the clinical success of mRNA-based vaccines for COVID-19, now is the right time to further push beyond the state of the art in RNA-based therapies.

Funded by the European Union (GA 101057491) and supported by the UK’s innovation agency, Innovate UK and the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 22.00119. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.